Our 3D ADPKD model system provides significant advancement in throughput and pathophysiologic relevancy.
See How It Works
Quality Communication
Exceptional Service
CustomizationDBM is a boutique biotechnology company founded in 2007 on the principle that if the end goal is to discover and use drugs for human patients, it makes the most sense to integrate the most relevant human cell platforms as early as possible into the drug discovery and validation process. We apply this principle to all our CRO and R&D projects.
Leveraging Human Cell Platform Technologies
DBM's mission is to fill a critical niche within the modern drug discovery industry by specializing in custom human cell engineering and human cell-based drug discovery.
Learn MoreWe are very positive on your customized and collaborative approach to CRO services projects. Your communication skills are excellent and we can tell that you work on that consistently. These factors helped us to decide to work with you on a long-term project.
Principal from a small Biotechnology company
The human taste bud cell cultures that you are developing and the bioassays that you have developed, along with the growth formats that you are implementing, could be game changers in a vigorous industry involving foods, beverages, food additives, food ingredients and the like.
Consultant familiar with the taste industry
Your company is one of a few if not the only Renal CROs globally and we have been searching for them vigorously recently.
Principal from a large BioPharmaceutical company client
Your 3D ADPKD cystogenesis assays are the most developed and are superior to other laboratories attempting to do the same profiling assays.
Principal from a small Biotechnology company
Your genotyped primary human ADPKD cells have been vitally important for our genomics studies in ADPKD.
Principal from a genomics unit within a large BioPharmaceutical company client
The biomarker data derived from your primary human ADPKD cell cultures from multiple donors matched our data derived from whole PKD kidney tissue.
Principal from a medium-sized Biotechnology company client
News & Publications
Check out our most recent publication in Molecular Pharmacology!
In this article, we share how we can use our human taste bud tissue-derived cell (hTBEC) cultures to identify small molecules to suppress bitterness associated with a commonly used anti-HIV…
Learn MoreDiscoveryBioMed, Inc. Is Proving to Be an Advantageous CRO for Artificial Intelligence (AI) Firms Focused on Drug Target and Discovery for Human Genetic Diseases and Human Diseases in General
DiscoveryBioMed, Inc. is a niche CRO that specializes in the creation and use of diseased and normal human cell platforms in ‘off the shelf’ and customized in vitro bioassays. Our services…
Learn MoreThe Sage Group Is Representing DiscoveryBioMed, Inc. Actively in M&A Partnering
DiscoveryBioMed, Inc. (DBM) is excited to announce that The Sage Group is actively representing the company and our multiple assets in M&A partnering conversations. “We met Bill Mason, Wayne Pambianchi,…
Learn More